Vancouver, Canada — February 6, 2026 — Leads & Copy —
Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) has entered into a development agreement with Polyrizon Ltd. (Nasdaq: PLRZ) to enhance the bioavailability and support clinical advancement of Clearmind’s lead MEAI candidate for addiction-related and other central nervous system (CNS) disorders.
The agreement engages Polyrizon, a pre-clinical-stage biotechnology company, to apply its proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind’s lead proprietary compound, MEAI (5-methoxy-2-aminoindane). MEAI is a next-generation, non-hallucinogenic neuroplastogen designed for the treatment of addiction-related disorders, weight loss, and other CNS conditions.
The collaboration integrates Clearmind’s expertise in non-hallucinogenic neuroplastogens with Polyrizon’s specialized intranasal delivery platform. The goal is to create a novel intranasal MEAI formulation to support Clearmind’s ongoing and future clinical development programs.
Clearmind aims to leverage key advantages of Polyrizon’s technology for intranasal delivery of MEAI, including:
Enhanced nasal residence time via specialized gel-like mechanisms, potentially improving bioavailability and duration of effect.
Targeted delivery of MEAI to improve therapeutic outcomes.
Optimized patient usability.
Formulation flexibility adapted to the physicochemical properties of MEAI, enabling tailored optimization.
Intranasal administration offers advantages for CNS-targeted therapeutics such as MEAI compared to traditional oral routes, including:
Bypassing first-pass metabolism for more direct systemic and CNS access.
Faster onset of absorption.
Lowering effective dose.
Dr. Adi Zuloff-Shani, Chief Executive Officer of Clearmind, said the company is pleased to partner with Polyrizon to develop an intranasal formulation for MEAI and believes the agreement reflects Clearmind’s proactive approach to innovative collaborations that accelerate progress and address unmet needs in addiction and mental health disorders.
Shares of Clearmind are listed for trading on Nasdaq under the symbol “CMND” and the Frankfurt Stock Exchange under the symbol “CWY0.”
Polyrizon is a development stage biotech company specializing in the development of innovative medical device hydrogels delivered in the form of nasal sprays. Polyrizon’s proprietary Capture and Contain TM, or C&C, hydrogel technology, comprised of a mixture of naturally occurring building blocks, is delivered in the form of nasal sprays, and potentially functions as a “biological mask” with a thin shield containment barrier in the nasal cavity.
Polyrizon is a related party of Clearmind. Clearmind is relying on the exemptions to a formal valuation and minority shareholder approval available to it pursuant to sections 5.5(a) and 5.7(1)(a) of MI61-101.
Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 31 granted patents.
For further information, visit:
https://www.clearmindmedicine.com
Or contact:
Investor Relations
invest@clearmindmedicine.com
Telephone: (604) 260-1566
US: CMND@crescendo-ir.com
General Inquiries
Info@Clearmindmedicine.com
Source: Clearmind Medicine Inc.
